{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:25:33Z","timestamp":1791465933179,"version":"4.3.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T08:46:33Z","timestamp":1710146793000},"page":"387-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Nail Psoriasis"],"prefix":"10.1016","volume":"42","author":[{"given":"Jonathan K.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/07853890.2022.2044511","article-title":"Optimal diagnosis and management of common nail disorders","volume":"54","author":"Lee","year":"2022","journal-title":"Ann Med"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib2","doi-asserted-by":"crossref","first-page":"xi","DOI":"10.1016\/j.det.2021.01.002","article-title":"Nail disorders: diagnosis and management","volume":"39","author":"Lipner","year":"2021","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","article-title":"Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus","volume":"81","author":"Rigopoulos","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000512688","article-title":"The impact of nail psoriasis and treatment on quality of life: a systematic review","volume":"7","author":"Stewart","year":"2021","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.det.2024.02.004_bib5","article-title":"The untold burden of isolated nail psoriasis: delayed diagnosis and significant risk of psoriatic arthritis in a retrospective study at an academic center [published online ahead of print, 2023 Jan 6]","author":"Chang","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib6","first-page":"138","article-title":"Clinical pearl: early diagnosis of nail psoriasis and psoriatic arthritis","volume":"99","author":"Lipner","year":"2017","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.det.2020.12.011","article-title":"Nail psoriasis in older adults: epidemiology, diagnosis, and topical therapy","volume":"39","author":"Ricardo","year":"2021","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.det.2020.12.012","article-title":"Nail psoriasis in older adults: intralesional, systemic, and biological therapy","volume":"39","author":"Ricardo","year":"2021","journal-title":"Dermatol Clin"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jaad.2021.12.017","article-title":"Poor coverage of psoriasis biologics in a cross-sectional analysis of Medicaid formularies","volume":"87","author":"Falotico","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib10","doi-asserted-by":"crossref","first-page":"e14276","DOI":"10.1111\/dth.14276","article-title":"Trends in psoriasis treatment 2005 to 2018: declining phototherapy utilization and concomitant increased use of biologics","volume":"33","author":"Do","year":"2020","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib11","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1111\/jdv.18611","article-title":"No association of metabolic syndrome with isolated nail psoriasis in a retrospective single-centre academic study","volume":"37","author":"Miller","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib12","first-page":"e13757","article-title":"Recommendations for treatment of nail psoriasis during the COVID-19 pandemic","volume":"33","author":"Ricardo","year":"2020","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.det.2024.02.004_bib13","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1111\/jdv.18435","article-title":"How to choose a systemic treatment for moderate-to-severe nail psoriasis","volume":"36","author":"Rigopoulos","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.02.004_bib14","article-title":"Efficacy and safety of nail psoriasis targeted therapies: a systematic review [published online ahead of print, 2023 May 20]","author":"Hwang","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2024.02.004_bib15","first-page":"1","article-title":"Safety of current systemic therapies for nail psoriasis [published online ahead of print, 2023 Jun 20]","author":"Hwang","year":"2023","journal-title":"Expet Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.det.2024.02.004_bib17","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jaad.2019.11.032","article-title":"Air cooling for improved analgesia during local anesthetic infiltration for nail surgery","volume":"84","author":"Ricardo","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib18","first-page":"76","article-title":"Pain-minimizing strategies for nail surgery","volume":"101","author":"Lipner","year":"2018","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/09546634.2018.1476647","article-title":"A\u00a0randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails","volume":"30","author":"Boontaveeyuwat","year":"2019","journal-title":"J\u00a0Dermatol Treat"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2133.1998.02031.x","article-title":"A\u00a0simplified protocol of steroid injection for psoriatic nail dystrophy","volume":"138","author":"de Berker","year":"1998","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.004_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1346-8138.2005.tb00882.x","article-title":"Efficacy of triamcinolone acetonide in various acquired nail dystrophies","volume":"32","author":"Grover","year":"2005","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/ced.15110","article-title":"A\u00a0pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis","volume":"47","author":"Starace","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.02.004_bib23","doi-asserted-by":"crossref","first-page":"e15660","DOI":"10.1111\/dth.15660","article-title":"Topical calcipotriol combined with urea 20% versus intralesional injection of triamcinolone acetonide, 5-fluorouracil, and methotrexate in the treatment of nail psoriasis: a comparative study","volume":"35","author":"Abdelmeniem","year":"2022","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/ijdvl.IJDVL_73_16","article-title":"Intramatricial injections for nail psoriasis: an open-label comparative study of triamcinolone, methotrexate, and cyclosporine","volume":"84","author":"Mittal","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ced.14933","article-title":"Intramatricial injection of anti-interleukin-17A antibody for six patients with nail psoriasis","volume":"47","author":"He","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2340\/00015555-0195","article-title":"Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study","volume":"87","author":"Rigopoulos","year":"2007","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2133.1998.02462.x","article-title":"Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid","volume":"139","author":"Tosti","year":"1998","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00015550252948220","article-title":"Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream","volume":"82","author":"Rigopoulos","year":"2002","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000202179","article-title":"Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment","volume":"218","author":"Rigopoulos","year":"2009","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D31T20Z9WW","article-title":"Topical calcipotriol therapy in nail psoriasis: a study of 24 cases","volume":"11","author":"Zakeri","year":"2005","journal-title":"Dermatol Online J"},{"issue":"5","key":"10.1016\/j.det.2024.02.004_bib31","first-page":"355","article-title":"Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study","volume":"68","author":"Scher","year":"2001","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib32","first-page":"363","article-title":"Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis","volume":"149","author":"Piraccini","year":"2014","journal-title":"G\u00a0Ital Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/idoj.idoj_222_21","article-title":"Topical tretinoin in the treatment of nail psoriasis","volume":"13","author":"Grover","year":"2022","journal-title":"Indian Dermatol Online J"},{"issue":"8","key":"10.1016\/j.det.2024.02.004_bib34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1468-3083.2012.04642.x","article-title":"Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study","volume":"27","author":"De Simone","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000068469","article-title":"Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study","volume":"206","author":"Cannav\u00f2","year":"2003","journal-title":"Dermatology"},{"issue":"12","key":"10.1016\/j.det.2024.02.004_bib36","first-page":"1083","article-title":"Erfolgreiche Lokalbehandlung der Nagelpsoriasis mit 5-Fluorouracil [Successful local treatment of nail psoriasis with 5-fluorouracil]","volume":"64","author":"Fritz","year":"1989","journal-title":"Z\u00a0Hautkr"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000018281","article-title":"Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study","volume":"199","author":"de Jong","year":"1999","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.det.2024.02.004_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/09546630902773494","article-title":"Yellow nails as an adverse reaction to the topical use of 5-fluorouracil for the treatment of nail psoriasis","volume":"20","author":"Fiallo","year":"2009","journal-title":"J\u00a0Dermatol Treat"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.02.004_bib40","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-3083.2010.03927.x","article-title":"Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study","volume":"25","author":"G\u00fcm\u00fc\u015fel","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10068","key":"10.1016\/j.det.2024.02.004_bib41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.det.2024.02.004_bib42","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3899\/jrheum.110242","article-title":"Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial","volume":"38","author":"Karanikolas","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/120347540400800208","article-title":"Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol","volume":"8","author":"Feliciani","year":"2004","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/archdermatol.2008.600","article-title":"Evaluation of the efficacy of acitretin therapy for nail psoriasis","volume":"145","author":"Tosti","year":"2009","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9494","key":"10.1016\/j.det.2024.02.004_bib46","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.det.2024.02.004_bib49","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr2.11180","article-title":"Evaluation of improvement in skin and nail psoriasis in bio-na\u00efve patients with active psoriatic arthritis treated with golimumab: results through week 52 of the GO-VIBRANT Study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14712598.2013.736960","article-title":"TNF-\u03b1 antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis","volume":"13","author":"Saraceno","year":"2013","journal-title":"Expet Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaad.2021.01.024","article-title":"Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis","volume":"85","author":"Huang","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-021-00388-8","article-title":"Ixekizumab demonstrates consistent efficacy versus adalimumab in biologic disease-modifying anti-rheumatic drug-na\u00efve psoriatic arthritis patients regardless of psoriasis severity: 52-week post hoc results from SPIRIT-H2H","volume":"9","author":"Kristensen","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib54","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","article-title":"Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S)","volume":"10","author":"Wasel","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2020.1749546","article-title":"Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials","volume":"33","author":"Elewski","year":"2022","journal-title":"J\u00a0Dermatol Treat"},{"issue":"5","key":"10.1016\/j.det.2024.02.004_bib57","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib58","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib59","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.004_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jdv.18572","article-title":"Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT","volume":"37","author":"Tsianakas","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2024.02.004_bib62","doi-asserted-by":"crossref","first-page":"e15506","DOI":"10.1111\/dth.15506","article-title":"Anti-IL23 for nail psoriasis in real life: results of efficacy and safety during a 52-week period","volume":"35","author":"Trovato","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib63","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J\u00a0Dermatol Treat"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib64","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib66","doi-asserted-by":"crossref","DOI":"10.25251\/skin.6.supp.49","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials","volume":"6","author":"Blauvelt","year":"2022","journal-title":"SKIN The Journal of Cutaneous Medicine"},{"issue":"1","key":"10.1016\/j.det.2024.02.004_bib67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.004_bib69","first-page":"1766","article-title":"AB1089 bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: pooled results through two years from the BE SURE AND BE RADIANT phase 3 trials","volume":"82","author":"Merola","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2024.02.004_bib70","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.det.2024.02.004_bib71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000520469","article-title":"Racial, ethnic, and sex disparities in nail psoriasis clinical trials: a systematic review","volume":"8","author":"Ricardo","year":"2022","journal-title":"Skin Appendage Disord"},{"issue":"6","key":"10.1016\/j.det.2024.02.004_bib72","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.jaad.2022.01.043","article-title":"Under-representation of racial and ethnic minorities in nail psoriasis randomized clinical trials: a call to action","volume":"86","author":"Ricardo","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.004_bib73","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1111\/ijd.16253","article-title":"Prioritization of race and ethnicity reporting and recruitment of diverse participants","volume":"62","author":"Chang","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2024.02.004_bib74","article-title":"Disparities in time to diagnosis and disease severity in skin of color patients with nail psoriasis: a retrospective analysis [published online ahead of print, 2023 Apr 5]","author":"Chang","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2024.02.004_bib75","first-page":"715","article-title":"Racial disparities in primary therapy for newly diagnosed psoriasis patients","volume":"22","author":"Miller","year":"2023","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.004_bib76","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1111\/ijd.16333","article-title":"Where are the older adults? Age distribution of nail psoriasis randomized clinical trials' participants: a systematic review","volume":"61","author":"Ricardo","year":"2022","journal-title":"Int J Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:39:07Z","timestamp":1716500347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000160"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Nail Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}